Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Bevacizumab ± Trastuzumab in First-Line Metastatic Breast Cancer
NCT00364611Phase 2Completed
- Sponsor
- Sanofi
- Start
- Aug 2006
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of docetaxel in breast cancer (2 arms), sponsored by Sanofi. Primary endpoints: Progression-free Survival Rate at 12 months and Time to Progression-free Survival. Started Aug 2006; status: completed.
02
Drugs
docetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00364611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00364611.